tbuckley/cabot-search huggingface dataset:
GENE-03. SPECIFIC SIGNATURES OF microRNA IN CEREBROSPINAL FLUID OF PATIENTS WITH PRIMARY BRAIN TUMORS AND METASTASES
Authors: Radim Jancalek, Martin Smrcka, Alena Kopkova, Jiri Sana, Marek Vecera, Jan Oppelt, Karolina Trachtova, Pavel Fadrus, Ondrej Slaby
Journal: Neuro-Oncology (2019)

Abstract Cerebrospinal fluid (CSF) baths extracellular environment of the central nervous system, and thus, it is ideal source of tumor diagnostic biomarkers like microRNAs (miRNAs), short non-coding RNAs involved in the pathogenesis of many cancers. As dysregulated levels of brain tumor specific miRNAs have been already observed in CSF, analysis of CSF miRNAs in brain tumor patients might help to develop new diagnostic platform. Next-Generation sequencing (NGS) was performed for analysis of small RNAs in 89 CSF samples taken from 32 glioblastomas (GBM), 14 low-grade gliomas (LGG), 11 meningiomas, 13 brain metastases and 19 non-tumor donors. Subsequently, according to NGS results levels of 10 miRNAs were measured in independent set of CSF samples (41 GBM, 44 meningiomas, 12 brain metastases and 20 non-tumor donors) using TaqMan Advanced miRNA Assays. NGS analysis revealed 22, 12 and 35 CSF miRNAs with significantly different levels in GBM, meningiomas, and brain metastases (adj.p &lt; 0.0005, adj.p &lt; 0.01, and adj.p &lt; 0.005) respectively, in comparison with non-tumor CSF samples. Subsequent validation of selected CSF miRNAs has confirmed different levels of 7 miRNAs in GBM, 2 in meningiomas, and 2 in brain metastases compared to non-tumors. Panel of miR-30e-5p and miR-140-5p was able to distinguish brain metastases with 65% sensitivity and 100% specificity compared to non-tumor samples (AUC = 0.8167); panel of miR-21-3p and miR-196-5p classified metastatic patients with 78% sensitivity and 92 % specificity in comparison to GBM (AUC = 0.90854) and with 75% sensitivity and 83% specificity compared to meningiomas (AUC = 0.84848). We have observed that CSFs from patients with various primary brain tumors and metastases are characterized by specific miRNA signatures. This work was supported by the Ministry of Health, Czech Republic grant nr. NV18-03-00398 and the Ministry of Education, Youth and Sports, Czech Republic under the project CEITEC 2020 (LQ1601).
Abstract 15519: Dietary Habits and Hypertension in Women of Child-Bearing Age: Dash Concordance in NHANES 2001-2016
Authors: Lara C Kovell, Benjamin Maxner, Didem Ayturk, Tiffany A Moore Simas, Colleen M Harrington, David D McManus, Gerard P Aurigemma, Stephen P Juraschek
Journal: Circulation (2019)

Background: Hypertension (HTN) in pregnancy is a leading cause of maternal mortality, and nearly 40% of maternal deaths from any cause have associated HTN. Although the Dietary Approaches to Stop H...
A Phase 2a Open-Label Study to Investigate Safety and Tolerability (including the MTD), Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of MT-3724 in Combination with Gemcitabine and Oxaliplatin in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Authors: Christine Burnett, Thomas Strack, Tara Lehner, Jack P Higgins, Deborah A. Katz, Matthew S. McKinney
Journal: Blood (2019)
Comparable Leukemia-Free Survival after Autologous Hematopoietic Cell Transplantation Versus HLA-Identical Sibling Hematopoietic Cell Transplantation for Adult Acute Myeloid Leukemia in First Complete Remission: A Registry Study By the Adult AML Working Group of the Japan Society for Hematopoietic Cell Transplantation
Authors: Motonori Mizutani, Masahiko Hara, Hiroyuki Fujita, Jun Aoki, Heiwa Kanamori, Shinichiro Machida, Satoshi Yamasaki, Kazuteru Ohashi, Kensuke Usuki, Takahiro Fukuda, Takaaki Chou, Junji Tanaka, Yoshiko Atsuta, Akiyoshi Takami
Journal: Blood (2014)
Expression of Notch Pathway Components in Primary Samples of Allogeneic Hematopoietic Cell Transplant Patients with Chronic Graft Versus Host Disease
Authors: Marcos Paulo Colella, Fernanda Soares Niemann, Beatriz Corey Morini, Matheus Lopes, Francisco José Penteado Aranha, Afonso Celso Vigorito, Sara T Olalla Saad, Patricia Favaro
Journal: Blood (2019)
Identification of Tablets
Authors: T. J. Carter
Journal: BMJ (1965)

EDIBAsL have facilities on their premises for the storage of vaccines under correct conditions.It would seem, therefore, that, even if effective and innocuous vaccines are produced by the manufacturers, there is a considerable chance that by the time they are administered to patients they will have lost much of their effectiveness, and may, in addition, possess a considerable toxicity.-Iam, etc. Leeds 16.
Targeted Inhibition of the NUP98-NSD1 Fusion Oncogene in AML
Authors: Sagarajit Mohanty, Nidhi Jyotsana, Amit Sharma, Basem Othman, Arnold Kloos, Madhvi Mandhania, Renate Schottmann, Euan Ramsay, Hans- Peter Vornlocher, Arnold Ganser, Felicitas Thol, Michael Heuser
Journal: Blood (2019)
Combination of a Cyclophosphamide-Total Body Irradiation Conditioning Regimen and Tacrolimus Plus Mycophenolate Mofetil for Gvhd Prophylaxis Is Associated with Higher HHV-6 Encephalitis Incidence after Cord Blood Transplantation
Authors: Takuto Mori, Nobuhiro Hiramoto, Ryosuke Ueda, Yoshimitsu Shimomura, Satoshi Yoshioka, Takayuki Ishikawa
Journal: Blood (2019)
FT576: A Novel Multiplexed Engineered Off-the-Shelf Natural Killer Cell Immunotherapy for the Dual-Targeting of CD38 and Bcma for the Treatment of Multiple Myeloma
Authors: Ryan Bjordahl, Svetlana Gaidarova, Jode P Goodridge, Sajid Mahmood, Greg Bonello, Megan Robinson, Chelsea Ruller, Mochtar Pribadi, Tom Lee, Ramzey Abujarour, Jason Dinella, Janel Huffman, Hui-yi Chu, Uta Hopken, Armin Rehm, Bahram Valamehr
Journal: Blood (2019)
NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019
Authors: Andrew D. Zelenetz, Leo I. Gordon, Jeremy S. Abramson, Ranjana H. Advani, Nancy L. Bartlett, Paolo F. Caimi, Julie E. Chang, Julio C. Chavez, Beth Christian, Luis E. Fayad, Martha J. Glenn, Thomas M. Habermann, Nancy Lee Harris, Francisco Hernandez-Ilizaliturri, Mark S. Kaminski, Christopher R. Kelsey, Nadia Khan, Susan Krivacic, Ann S. LaCasce, Amitkumar Mehta, Auayporn Nademanee, Rachel Rabinovitch, Nishitha Reddy, Erin Reid, Kenneth B. Roberts, Stephen D. Smith, Erin D. Snyder, Lode J. Swinnen, Julie M. Vose, Mary A. Dwyer, Hema Sundar
Journal: Journal of the National Comprehensive Cancer Network (2019)

Diffuse large B-cell lymphomas (DLBCLs) and follicular lymphoma (FL) are the most common subtypes of B-cell non-Hodgkin’s lymphomas in adults. Histologic transformation of FL to DLBCL (TFL) occurs in approximately 15% of patients and is generally associated with a poor clinical outcome. Phosphatidylinositol 3-kinase (PI3K) inhibitors have shown promising results in the treatment of relapsed/refractory FL. CAR T-cell therapy (axicabtagene ciloleucel and tisagenlecleucel) has emerged as a novel treatment option for relapsed/refractory DLBCL and TFL. These NCCN Guidelines Insights highlight important updates to the NCCN Guidelines for B-Cell Lymphomas regarding the treatment of TFL and relapsed/refractory FL and DLBCL.
Initial Imaging-Guided Strategy Versus Routine Care in Patients With Non–ST-Segment Elevation Myocardial Infarction
Authors: Martijn W Smulders, Bas L J H Kietselaer, Joachim E Wildberger, Pieter C Dagnelie, Hans-Peter Brunner-La Rocca, Alma M A Mingels, Yvonne J M van Cauteren, Ralph A L J Theunissen, Mark J Post, Simon Schalla, Sander M J van Kuijk, Marco Das, Raymond J Kim, Harry J G M Crijns, Sebastiaan C A M Bekkers
Journal: Journal of the American College of Cardiology (2019)
Real-World Efficacy of Eculizumab for Paroxysmal Nocturnal Hemoglobinuria in South Korea: Paradox of Eculizumab
Authors: Ka-Won Kang, Hyemi Moon, Byung-Hyun Lee, Min Ji Jeon, Eun Sang Yu, Dae Sik Kim, Se Ryeon Lee, Hwa Jung Sung, Seok Jin Kim, Chul Won Choi, Byung Soo Kim, Juneyoung Lee, Yong Park
Journal: Blood (2019)
Analysis of Micro-RNAs Associated to Treatment Failure in Diffuse Large B Cell Lymphoma
Authors: Leyre Bento, Teresa Ros, Josep Muncunill, Víctor Asensio, Concepción Fernández, Adriana Marcela Quintero, Adriana Sas, Jordi Martínez-Serra, Blanca Sánchez-González, Oliver Vögler, Sandra Pérez, Marta García-Recio, Sara Aida Jiménez-Julià, Gaspar Aspas, Raquel Del Campo, Javier Ibarra, Rafael Ramos, Antonio Salar, Antonia Sampol, Regina Alemany, Antonio Gutiérrez
Journal: Blood (2019)
A Comparison of Droplet Digital PCR and RT-qPCR for BCR-ABL1 Monitoring in Chronic Myeloid Leukemia
Authors: Carmen Fava, Paola Berchialla, Jessica Petiti, Maria Teresa Bochicchio, Barbara Izzo, Emilia Giugliano, Emanuela Ottaviani, Santa Errichiello, Giovanna Rege Cambrin, Claudia Venturi, Luigiana Luciano, Filomena Daraio, Daniele Calistri, Alessandro Martino, Giuseppe Saglio, Giovanni Martinelli, Fabrizio Pane, Daniela Cilloni, Enrico Marco Gottardi
Journal: Blood (2019)
Outcome of Patients with Newly-Diagnosed Therapy-Related AML (t-AML) and AML with Myelodysplasia-Related Changes (AML-MRC) Treated with Liposomal Daunorubicin and Cytarabine (CPX-351) at an Academic Community-Based Health System
Authors: John Khoury, Nwabundo Anusim, David Macari, Angela Duenn, Ishmael Jaiyesimi
Journal: Blood (2019)
Preliminary Results from a Phase I Study of SHC014748M in Patients with Relapsed or Refractory Indolent B-Cell Lymphomas
Authors: Wei Xu, Jie Jin, Keshu Zhou, Li Wang, Huayuan Zhu, Jiejing Qian, Jianying Huang, Fuling Zhou, Xiaohong Xu, Zhiqiang Wang, Wei Guo, Jianyong Li
Journal: Blood (2019)
EXTH-67. IDENTIFICATION AND DEVELOPMENT OF NEURAL ECM-BINDING LAMPREY ANTIBODIES (VARIABLE LYMPHOCYTE RECEPTORS) THAT TARGET GLIOBLASTOMA
Authors: Benjamin Umlauf, Paul Clark, Jason Lajoie, Julia Georgieva, Samantha Bremner, Brantley Herrin, Eric Shusta, John Kuo
Journal: Neuro-Oncology (2019)

Abstract INTRODUCTION The median survival of glioblastoma (GBM) patients remains less than two years even with state-of-the-art treatment. Current targeted GBM therapies demonstrate initial therapeutic benefit; however, patients relapse due to therapeutic selection of treatment resistant GBM cellular populations. Therefore, we propose targeting pathologic disruption of the blood brain barrier (BBB) via exposure of neural ECM, rather than disease markers, to overcome therapy-resistant GBM. METHODS We identify Variable Lymphocyte Receptors (VLRs, the antigen recognition system used by lamprey) that demonstrate high specificity for neural ECM. Candidate VLRs underwent further refinement using in vitro binding assays and ex vivo tissue staining. Utilizing pathologic disruption of BBB as an approach for targeting GBM was confirmed in vivo using intracranial murine glioblastoma models. RESULTS The lead neural ECM-binding VLR candidate, named P1C10, demonstrates diffuse binding to parenchymal neural ECM, without detectable binding to other tissues. P1C10 demonstrates nanomolar affinity for in vitro derived neural ECM, and preferentially accumulates at intracranial GL261 and U87 lesions in murine GBM models. Finally, administration of P1C10-targeted doxorubicin-loaded liposomes significantly extends the survival of mice bearing intracranial U87 GBM. CONCLUSIONS We identified VLRs that bind neural ECM, and demonstrate their utility for delivering compounds and nanoparticles to sites of GBM induced blood brain barrier disruption. This novel strategy allows for targeting therapeutics via the underlying physiology of GBM rather than relying on cellular disease markers that are often lost in patients that relapse after targeting therapies.
Minimal Residual Disease Assessment Using Euroflow-NGF in Patients with Multiple Myeloma Treated with a Combination of Carfilzomib, Lenalidomide, and Dexamethasone (KRD)
Authors: Takeshi Yoroidaka, Hiroyuki Takamatsu, Takeshi Yamashita, Ryoichi Murata, Kyoko Yoshihara, Satoshi Yoshihara, Mikio Ueda, Shinji Nakao, Kosei Matsue
Journal: Blood (2019)
Belinostat Induces High Overall Response Rate (ORR) in Patients with Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL)
Authors: Ahmed Sawas, Helen Ma, Andrei Shustov, Pamela Hsu, Gajanan Bhat, Mark Acosta, Steven M. Horwitz, Owen A. O'Connor
Journal: Blood (2019)
ACTR-56. PHASE II TRIAL OF NILOTINIB IN PDGFR-ALPHA ENRICHED RECURRENT GLIOBLASTOMA
Authors: David Picconi, Tiffany Juarez, Santosh Kesari
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND This phase II study was designed to determine the efficacy of nilotinib in a biomarker-selected population of recurrent glioblastoma (GBM), enriched for platelet-derived growth factor receptor-alpha (PDGFR-alpha) activation. Nilotinib is a multi-kinase inhibitor approved as treatment for Philadelphia-chromosome/Bcr-Abl chronic myelogenous leukemia. In addition to targeting Bcr-Abl tyrosine kinase, it also inhibits PDGFR-alpha signaling. METHODS Patients with recurrent GBM, with either PDGFR-alpha amplification or PDGFR-alpha overexpression by immunohistochemistry (IHC) were enrolled in a single-arm, single institution phase II study. Nilotinib was administered at 400 mg twice a day. The primary end point was progression-free survival at 6 months (PFS6). Secondary end points were safety, overall survival (OS) and Objective Response Rate (ORR). RESULTS 34 patients were treated (22 IDH-wild type GBM, 2 IDH-mutant GBM, 10 GBM NOS). 26 were male and 8 were female. Median age was 55.5 (range 22–78 years). Four patients had PDGFR-alpha amplification, and 30 had overexpression by IHC. Median lines of prior therapy were 1 (range 1–7). 6/34 patients (18%) experienced related adverse events grade ≥ 3. There were no grade 5 events. The PFS6 was 9% (3/34), and PFS12 was 6% (2/34). Median PFS was 1.3 months and the median OS was 6.6 months. Best response was stable disease (SD) for 8 patients and complete response (CR) for one patient. ORR was 1/34 patients (3%). The patient with a CR was IDH-wild type, unmethylated, had PDGFR-alpha overexpression by IHC, and had a durable response &gt; 5 years. CONCLUSION Nilotinib had limited activity in recurrent GBM enriched for PDGFR-alpha, although there were a small number of durable responders. Further molecular characterization is warranted to determine additional biomarkers of response that could be used to select patients that may benefit from nilotinib.
Diseases of the Kidney
Authors: Claus Brun, Tage Hilden, Poul Iversen, Flemming Raaschou
Journal: Annual Review of Medicine (1956)

Diseases of the Kidney, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/med/7/1/annurev.me.07.020156.001333-1.gif
Acid‐suppressive medication as a possible risk factor for late‐onset asthma
Authors: Yasuhiro Tomita, Yuma Fukutomi, Mari Irie, Kazuhiro Azekawa, Hiroaki Hayashi, Yosuke Kamide, Kiyoshi Sekiya, Yoichi Nakamura, Chiharu Okada, Terufumi Shimoda, Yoshinori Hasegawa, Masami Taniguchi
Journal: Allergy (2019)

Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
A Phase I/II Study of NMS-03592088, a FLT3, KIT and CSF1R Inhibitor, in Patients with Relapsed or Refractory AML or CMML
Authors: Marina Ciomei, Lucia Zanetta, Federico Lussana, Erika Ravelli, Francesco Fiorentini, Roberta Bosotti, Elena Ardini, Andrea Lombardi Borgia, Romana Pulci, Rosalinda Gatto, Alessandro Di Sanzo, Elena Colajori, Cristina Davite, Arturo Galvani, Frank Xiaodong Gan, Giuseppe Rossi, Matteo Giovanni Della Porta, Roberto Cairoli, Alessandro Rambaldi, Antonella Isacchi
Journal: Blood (2019)
CNAs concordance between CRC-PDOs and the original tissue reveals relevant oncogenic pathways alterations
Authors: J. Castillo, F. Papaccio, F.G. Valiente, M.F. Gutierrez-Bravo, M. Cabeza-Segura, V. Gambardella, M.D.S. Huerta, C. Martinez-Ciarpaglini, C. Alfaro-Cervello, P. Rentero-Garrido, S. Zúñiga-Trejos, S. Rosello Keranen, T. Fleitas, N. Tarazona, D. Roda Perez, A. Cervantes
Journal: Annals of Oncology (2019)
Loss-of-Function and Gain-of-Function Consequences of GATA2 Disease Mutations
Authors: Koichi Ricardo Katsumura, Peng Liu, Charu Mehta, Kyle J Hewitt, Alexandra Soukup, Isabela J Fraga de Andrade, Erik A. Ranheim, Kirby D Johnson, Emery H Bresnick
Journal: Blood (2019)
A Phase 2 Study of MT-3724 to Evaluate Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Authors: Daniel O. Persky, Vasile Musteata, Mamia Zodelava, Tetiana Perekhrestenko, Adolfo E Diaz, Troy H. Guthrie, Thomas Strack, Christine Burnett, Sarah Wilson, Tara Baetz
Journal: Blood (2019)
DNA methylation-based classification reveals difference between pediatric T-cell acute lymphoblastic leukemia and normal thymocytes
Authors: Shunsuke Kimura, Masafumi Seki, Tomoko Kawai, Hiroaki Goto, Kenichi Yoshida, Tomoya Isobe, Masahiro Sekiguchi, Kentaro Watanabe, Yasuo Kubota, Yasuhito Nannya, Hiroo Ueno, Yusuke Shiozawa, Hiromichi Suzuki, Yuichi Shiraishi, Kentaro Ohki, Motohiro Kato, Katsuyoshi Koh, Ryoji Kobayashi, Takao Deguchi, Yoshiko Hashii, Toshihiko Imamura, Atsushi Sato, Nobutaka Kiyokawa, Atsushi Manabe, Masashi Sanada, Marc R. Mansour, Akira Ohara, Keizo Horibe, Masao Kobayashi, Akira Oka, Yasuhide Hayashi, Satoru Miyano, Kenichiro Hata, Seishi Ogawa, Junko Takita
Journal: Leukemia (2019)
A Phase I/II Study to Examine the Safety and Efficacy of Pembrolizumab 200 Mg Fixed Dose Administered Every 3 Weeks (Q3W) in Combination with Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)
Authors: Swami P. Iyer, Sattva S Neelapu, Ethan Burns, Ranjit Nair, Chitra Hosing, Yago Nieto, Jason R. Westin, Simrit Parmar, Nathan H. Fowler, Loretta J. Nastoupil, Madeleine Duvic, Roberto N. Miranda, Hun Ju Lee, Felipe Samaniego, Sairah Ahmed, Feng Lei, Auris Huen
Journal: Blood (2019)
Hexokinase II Expression As a Prognosis Marker in Diffuse Large B-Cell Lymphoma (DLBCL) Pre- and Post- the Incorporation of Rituximab to Standard CHOP Chemotherapy
Authors: Juan J. Gu, Yizhen Liu, Jia Jin, Ling Yang, Zuguang Xia, Xiaojian Liu, Fangfang Lv, Francisco J. Hernandez-Ilizaliturri, Xiaonan Hong, Junning Cao, Qunling Zhang
Journal: Blood (2019)
Guided Polarization of iPSC-Derived CD4SP Helper T Cells By CRISPR/Cas9-Based Genome-Editing
Authors: Hisashi Yano, Tokuyuki Shinohara, Keiko Koga, Shoichi Iriguchi, Yasuyuki Miyake, Xuewei Song, Megumi Tada, Yoshiaki Kassai, Hitoshi Kiyoi, Shin Kaneko
Journal: Blood (2019)
A Window Study of Ixazomib in Untreated B-NHL
Authors: Solomon A. Graf, Ryan C. Lynch, Chaitra S. Ujjani, David G. Coffey, Andrew J. Cowan, Stephen D. Smith, Mazyar Shadman, Edus H. Warren, Edward N. Libby, Colin D. Godwin, Ryan D. Cassaday, Ted A Gooley, Jonathan R. Fromm, Ajay K. Gopal
Journal: Blood (2019)
PATH-60. PRIMARY CNS LYMPHOMA PRECEDED BY ACUTE DEMYELINATION
Authors: Justin Low, Anne Buckley, Dina Randazzo
Journal: Neuro-Oncology (2019)

Abstract Primary CNS lymphoma commonly presents with nonspecific encephalopathy or focal neurologic deficits. Magnetic resonance imaging typically shows a homogeneously enhancing mass with surrounding edema. The imaging differential diagnosis is broad, and includes high grade glioma and neuroinflammatory conditions. Definitive diagnosis therefore requires biopsy. Here we present a case of primary CNS lymphoma that was diagnosed as an acute demyelinating process on initial biopsy. A 68 year old female presented with gait instability and vertigo. MRI showed right cerebellar and right trigonal enhancing lesions. Biopsy revealed an acute demyelinating inflammatory process and she was diagnosed with acute disseminated encephalomyelitis. She was treated with intravenous methylprednisolone followed by oral prednisone with resulting clinical and radiographic improvement. She was re-admitted to hospital 4 months later with encephalopathy. Imaging showed a new enhancing mass in the pericallosal frontal lobes. Repeat brain biopsy showed diffuse large B-cell lymphoma. This case illustrates a highly unusual situation of biopsy-proven central demyelination preceding a primary CNS lymphoma diagnosis. It raises a number of etiopathological questions concerning the coexistence and potential causal relationships between demyelination and lymphoma. Additionally, it highlights the need for repeat biopsy if clinical and radiographic suspicion for lymphoma persists despite an alternative initial biopsy result.
RTHP-33. A SINGLE INSTITUTION RETROSPECTIVE ANALYSIS ON SURVIVAL BASED ON TREATMENT PARADIGMS FOR PATIENTS WITH ANAPLASTIC OLIGODENDROGLIOMA
Authors: Jacob Young, Yalan Zhang, Annette Molinaro, Jennie Taylor, Jennifer Clarke, Michael Prados, Susan Chang, Mitchel Berger, Nicholas Butowski, Nancy Ann Oberheim-Bush
Journal: Neuro-Oncology (2019)

Abstract Anaplastic oligodendrogliomas are a type of high grade glioma defined molecularly by the 1p19q co-deletion. Currently, there is no curative therapy, and some studies have estimated median survival is estimated to be approximately 5 years. Current standard of care includes surgical resection followed by radiation and chemotherapy. However, the benefit of up-front radiation with chemotherapy compared to chemotherapy alone following surgical resection has not been shown in a randomized control trial. Given the long-term cognitive consequences of radiation therapy and the high percentage of patients who lives beyond 15 years with AO, there is an effort to balance longevity with radiation toxicity. As such we performed a retrospective single institution analysis of survival of patients with anaplastic oligodendroglioma over 20 years. 159 patients were identified as diagnosed with an anaplastic oligodendroglioma between 1996–2016. Of those, 57 patients were found to have anaplastic olidodendroglioma at original diagnosis and had long term follow-up. Sixty-six percent of patients were between the ages of 30–50 and mean KPS was 87.3. At the time of analysis, 33% of patients had died. In this cohort, 60% of patients were initially treated with radiation and chemotherapy (either temozolomide or CCNU) at diagnosis and 40% were treated with chemotherapy alone. Median overall survival for the entire cohort was 142 months. The related risk of progression in the upfront chemotherapy only group is approximately 5.87 times higher than the patients who received radiation and chemotherapy (Hazard ratio=5.87, 1.92–17.90, p=0.002). However, there was no significant difference in overall survival in patients treated with upfront chemotherapy compared to patients treated upfront with chemotherapy and radiation (p=0.14). On univariate analysis, there was no association between age, KPS, EOR, or upfront vs. delayed radiation and survival. As such initial treatment with chemotherapy alone may be an option for some patients with anaplastic oligodendroglioma.
Should Psychiatrists Tell?
Authors: H. Pullar-Strecker
Journal: BMJ (1964)

when in fact most of these calls are quite genuine and are very frequently to see a feverish child who has become progressively more ill during the day, and about whom the parents are extremely worried.Under the present system of payment, of course, one resents these calls very much indeed.How differently would one feel about them if there were a special system of payment, over and above the present payment, and not deductible from the Pool, of one guinea for each new call made between the hours of 5 p.m. and 8 a.m.There must be very few doctors who do not have to do at least 500 such calls each year.Instead of grumbling about these extra calls after a hard day's work, one should ask why it is that we do not recognize these calls as inevitable, insist on being paid adequately for them, but not out of the Pool, and do them with a rather better grace than is per- haps possible at present.I think that one guinea would be a fair payment, and that it should certainly not be borne by the patient, but by the Health Service.I consider that the following would be a suitable form for claiming the fee of one guinea from the National Health Service: